Indeed, we prospectively conducted a phase II clinical trial (ChiCTR2000032317) evaluating the combination efficacy of anti‐PD1, antiangiogenic agent, and TPC chemotherapy in high‐risk NPC patients (TanyN3M0).9 The gene discussed is PDCD1; the disease is nasopharyngeal carcinoma.